AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events
For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
